The study of the sera TRAIL levels in chronic hepatitis B patients treated with Nucleoside analogues
- VernacularTitle:核苷类似物早期病毒学应答慢性乙型肝炎患者血清sTRAIL水平变化及意义
- Author:
Ping WEI
;
Hua WANG
;
Linglan ZENG
;
Li ZHU
- Publication Type:Journal Article
- Keywords:
sTRAIL;
Chronic hepatitis B;
Nucleoside;
Early anti-viral response
- From:
Chinese Journal of Immunology
2010;26(2):174-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the sTRAIL levels in chronic hepatitis B(CHB) patients upon nucleoside analogues therapy.Methods:Serial sera of 60 CHB patients before and after nucleoside analogues therapy were collected,among which there were 20 complete responding cases,20 partial responding cases,20 non-responding cases,and 10 healthy people.The level of sTRAIL,IFN-γ and ALT were detected.Results:The level of sTRAIL,IFN-γ and ALT of CHB patients were higher than that of normal group.The sTRAIL level of complete responding group at 4 weeks and partial responding group at 12 weeks were lower than those before therapy,while serum TRAIL of complete responding group were lower than those of partial responding group at 4 weeks.The IFN-γ level of complete responding group at 4 weeks and partial responding group at 12 weeks were higher than those before therapy.ALT levels of all groups in the course of therapy declined gradually and significant difference was observed at different time point.Conclusion:Serum TRAIL level can be used as an early marker for efficacy of nucleoside analogues therapy efficacy in CHB patients.sTRAIL may play a role in restoring immune injury of early anti-viral response in patients with hepatitis B.
